Literature DB >> 11592104

Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.

S B Fox1, M Taylor, J Grøndahl-Hansen, S Kakolyris, K C Gatter, A L Harris.   

Abstract

The generation of urokinase plasminogen activator (uPA) by tumours is an important pathway for neoplastic cell invasion and metastasis. Indeed in several tumour types, elevated levels of uPA, its receptor (uPAR) or its inhibitor plasminogen activator inhibitor-1 (PAI-1) is associated with a poorer prognosis. Since endothelial cells also use this proteolytic system to remodel the extracellular matrix during angiogenesis and since angiogenesis, as assessed by microvessel density, is also a predictor of patient survival, this study was designed to investigate the relationship between angiogenesis and the urokinase system in breast tumours. The aims were to assess whether the uPA, uPAR and/or PAI-1 correlates with angiogenic activity and could therefore be a useful objective clinical measure of tumour neovascularization; and to clarify whether the poor outcome associated with high levels of the urokinase system is due to its association with angiogenesis. The study also sought to examine the relationship between the uPA system and vessel remodelling using loss of a basement membrane epitope (LH39) normally associated with established capillaries. The cytosolic levels of uPA, PAI-1 and uPAR were therefore measured by enzyme linked immunoabsorbent assay, together with tumour vascularity, in 136 well-characterized invasive breast carcinomas. There were significant relationships between uPA and uPAR (Spearman r=0.37, p<0.0001), uPA and PAI-1 (Spearman r=0.19, p=0.03) and between uPAR and PAI-1 (Spearman r=0.23 p=0.01). A significant correlation was also observed between PAI-1 and vessel remodelling (Spearman r=0.34, p=0.04), patient age (p=0.01), nodal status (p=0.047) and tumour grade (p=0.04), but no association between tumour vascularity and PAI (p=0.96), uPA (p=0.69) or uPAR (p=0.81) was present. No significant association was seen between any of the urokinase variables and expression of the angiogenic factor thymidine phosphorylase. Furthermore, no significant associations were found between any of the studied parameters and overall survival in a univariate analysis of the cancer patients. A multivariate Cox proportional hazard model of overall survival showed that uPA (p=0.15), but not uPAR (p=0.52) or PAI-1 (p=0.61), gave no additional prognostic information. These findings show that uPA may work via an independent pathway to angiogenesis and therefore combined blockade of uPA and angiogenesis may have additional therapeutic benefits. It also shows, as recently demonstrated in animal models, that PAI-1 may be a key regulator of vascular remodelling in human cancer. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11592104     DOI: 10.1002/path.931

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  11 in total

Review 1.  The macrophage growth factor CSF-1 in mammary gland development and tumor progression.

Authors:  Elaine Y Lin; Valerie Gouon-Evans; Andrew V Nguyen; Jeffrey W Pollard
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

2.  Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression.

Authors:  Gabriel Scicolone; Viviana Sanchez; Liliana Vauthay; Federico Fuentes; Alejandro Scicolone; Lorenzo Scicolone; Melina Rapacioli; Vladimir Flores
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-21       Impact factor: 4.553

3.  A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.

Authors:  Tongjian Cai; Xueyong Li; Jin Ding; Wenjing Luo; Jingxia Li; Chuanshu Huang
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

Review 4.  The prognostic molecular markers in hepatocellular carcinoma.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

Review 5.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

6.  Quantitative detection of common deletion of mitochondrial DNA in hepatocellular carcinoma and hepatocellular nodular hyperplasia.

Authors:  Jian-Yong Shao; Hong-Yi Gao; Yu-Hong Li; Yu Zhang; You-Yong Lu; Yi-Xin Zeng
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

7.  Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.

Authors:  Dragomir P Zubac; Tore Wentzel-Larsen; Tomas Seidal; Leif Bostad
Journal:  BMC Urol       Date:  2010-12-03       Impact factor: 2.264

8.  Transforming growth factor-β promotes aggressiveness and invasion of clear cell renal cell carcinoma.

Authors:  Raviprakash T Sitaram; Pramod Mallikarjuna; Maréne Landström; Börje Ljungberg
Journal:  Oncotarget       Date:  2016-06-14

9.  Obesity and breast cancer: the roles of peroxisome proliferator-activated receptor-γ and plasminogen activator inhibitor-1.

Authors:  Jennifer C Carter; Frank C Church
Journal:  PPAR Res       Date:  2009-08-06       Impact factor: 4.964

10.  Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients.

Authors:  S Hansen; J Overgaard; C Rose; Ann Knoop; A-V Laenkholm; J Andersen; F B Sørensen; P A Andreasen
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.